Biomarkers in asthma and allergic rhinitis

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 6, 2010, Pages 468-481

  Diamant, Z ^a   Boot, J D ^b   Mantzouranis, E ^c   Flohr, R ^d   Sterk, P J ^e   Gerth van Wijk, R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HAL Allergy   (Netherlands)

^c UNIVERSITY OF CRETE   (Greece)

^d LEIDEN UNIVERSITY   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Allergic rhinits; Asthma; Biomarkers; Non invasive

Indexed keywords

BIOLOGICAL MARKER; HISTAMINE; METHACHOLINE; NITRIC OXIDE;

ALLERGIC REACTION; ALLERGIC RHINITIS; ASTHMA; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; HUMAN; LABORATORY DIAGNOSIS; NON INVASIVE MEASUREMENT; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SPIROMETRY; TREATMENT RESPONSE;

ASTHMA; BIOLOGICAL MARKERS; CHILD; HUMANS; RHINITIS; SPECIMEN HANDLING;

EID: 78649335507     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.06.006     Document Type: Review

References (236)

1. Bousquet J., Khaltaev N., Cruz A.A., Denburg J., Fokkens W.J., Togias A., et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008, 63(Suppl. 86):8-160.
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Bethersda/Martyland: NHLBI/WHO workshop report. [Last updated 2009]. http://www.ginasthma.com.
3. Vercelli D. Gene-environment interactions in asthma and allergy: the end of the beginning?. Curr Opin Allergy Clin Immunol 2010 Apr, 10(2):145-148.
4. Von Mutius E. Gene-environment interactions in asthma. J Allergy Clin Immunol 2009, 123(1):3-11.
5. Boot J.D., Panzner P., Diamant Z. A critical appraisal of methods used in early clinical development of novel drugs for the treatment of asthma. Pulm Pharmacol Ther 2007, 20(3):201-219. [Review].
6. Bousquet J., van Cauwenberge P., Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108(5 Suppl.):S147-S334.
7. Jeffery P., Haahtela T. Allergic rhinitis and asthma: inflammation in a one-airway condition. BMC Pulm Med 2006, 6(Suppl. 1):S5. [12 pages].
8. Kaiko G.E., Horvat J.C., Beagley K.W., Hansbro P.M. Immunological decision-making: how does the immune system decide to mount a helper T-cell response?. Immunology 2008 Mar, 123(3):326-338.
9. Poulsen L.K., Hummelshoj L. Triggers of IgE class switching and allergy development. Ann Med 2007, 39(6):440-456.
10. Holgate S.T. Has the time come to rethink the pathogenesis of asthma?. Curr Opin Allergy Clin Immunol 2010 Feb, 10(1):48-53.
11. Ziegler S.F., Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol 2010 Mar 19, 11(4):289-293.
12. Tanaka J., Watanabe N., Kido M., Saga K., Akamatsu T., Nishio A., et al. Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions. Clin Exp Allergy 2009 Jan, 39(1):89-100.
13. Bradding P., Green R.H. Subclinical phenotypes of asthma. Curr Opin Allergy Clin Immunol 2010 Feb, 10(1):54-59.
14. Anderson G.P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008 Sep 20, 372(9643):1107-1119.
15. Luskin A.T. What the asthma end points we know and love do and do not tell us. J Allergy Clin Immunol 2005, 115(4, Suppl. 1):S539-S545.
16. Rosi E., Ronchi M.C., Grazzini M., Duranti R., Scano G. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J Allergy Clin Immunol 1999, 103(2):232-237.
17. Leung T.F., Wong G.W., Ko F.W., Lam C.W., Fok T.F. Clinical and atopic parameters and airway inflammatory markers in childhood asthma: a factor analysis. Thorax 2005, 60(10):822-826.
18. Haldar P., Pavord I.D., Shaw D.E., Berry M.A., Thomas M., Brightling C.E., et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008 Aug 1, 178(3):218-224.
19. Moore W.C., Meyers D.A., Wenzel S.E., Teague W.G., Li H., Li X., et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010 Feb 15, 181(4):315-323.
20. Diamant Z. Should pathophysiology have implications on the management of asthma?. Int J Respir Care 2005, 1(spring):22-27. (Invited state of art).
21. Diamant Z., Boot D., Kamerling I., Bjermer L. Methods used in clinical development of novel antiasthma therapies. Respir Med 2008, 102(3):332-338.
22. Lesko L.J., Atkinson A.J. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies 1. Annu Rev Pharmacol Toxicol 2001, 41(1):347-366.
23. Atkinson A.J., Colburn W.A., DeGruttola V.G., DeMets D.L., Downing G.J., Hoth D.F., et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69(3):89-95.
24. Critical Path Initiative; FDA http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative.
25. Wenzel S.E., Schwartz L.B., Langmack E.L., Halliday J.L., Trudeau J.B., Gibbs R.L., et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999, 160(3):1001-1008.
26. Adelroth E. How to measure airway inflammation: bronchoalveolar lavage and airway biopsies. Can Respir J 1998 Jul-Aug, (5 Suppl. A):18A-21A.
27. Balzar S., Wenzel S.E., Chu H.W. Transbronchial biopsy as a tool to evaluate small airways in asthma. Eur Respir J 2002 Aug, 20(2):254-259.
28. Macedo P., Hew M., Torrego A., Jouneau S., Oates T., Durham A., et al. Inflammatory biomarkers in airways of patients with severe asthma compared with non-severe asthma. Clin Exp Allergy 2009 Nov, 39(11):1668-1676.
29. Murugan A., Prys-Picard C., Calhoun W.J. Biomarkers in asthma. Curr Opin Pulm Med 2009 Jan, 15(1):12-18.
30. Silkoff P.E., Trudeau J.B., Gibbs R., Wenzel S.E. The relationship of induced-sputum inflammatory cells to BAL and biopsy. Chest 2003 Mar, 123(3 Suppl.):371S-372S.
31. Lemière C., Ernst P., Olivenstein R., Yamauchi Y., Govindaraju K., Ludwig M.S., et al. Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and non-eosinophilic phenotypes. J Allergy Clin Immunol 2006 Nov, 118(5):1033-1039.
32. Paggiaro P.L., Chanez P., Holz O., Ind P.W., Djukanović R., Maestrelli P., et al. Sputum induction. Eur Respir J Suppl 2002 Sep, 37:3s-8s. [Review].
33. Efthimiadis A., Spanevello A., Hamid Q., Kelly M.M., Linden M., Louis R., et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl 2002 Sep, 37:19s-23s.
34. Pizzichini E., Pizzichini M.M., Efthimiadis A., Evans S., Morris M.M., Squillace D., et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996 Aug, 154(2 Pt 1):308-317.
35. Pizzichini E., Pizzichini M.M., Efthimiadis A., Hargreave F.E., Dolovich J. Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur Respir J 1996 Jun, 9(6):1174-1180.
36. Djukanovic R., Sterk P.J., Fahy J.V., Hargreave F.E. Standardised methodology of sputum induction and processing. Eur Respir J 2002 Jul 1, 20(37 Suppl.):1S-2S.
37. Spanevello A., Migliori G.B., Sharara A., Ballardini L., Bridge P., Pisati P., et al. Induced sputum to assess airway inflammation: a study of reproducibility. Clin Exp Allergy 1997 Oct, 27(10):1138-1144.
38. Corrigan C.J., Kay A.B. T cells and eosinophils in the pathogenesis of asthma. Immunol Today 1992 Dec, 13(12):501-507.
39. Wenzel S. Mechanisms of severe asthma. Clin Exp Allergy 2003 Dec, 33(12):1622-1628.
40. Louis R., Sele J., Henket M., Cataldo D., Bettiol J., Seiden L., et al. Sputum eosinophil count in a large population of patients with mild to moderate steroid-naive asthma: distribution and relationship with methacholine bronchial hyperresponsiveness. Allergy 2002 Oct, 57(10):907-912.
41. Louis R., Lau L., Bron A., Roldaan A., Radermecker M., Djukanovic R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000 Jan 1, 161(1):9-16.
42. Jatakanon A., Lim S., Barnes P.J. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000 Jan 1, 161(1):64-72.
43. in't Veen J.C., Smits H.H., Hiemstra P.S., Zwinderman A.E., Sterk P.J., Bel E.H. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. Am J Respir Crit Care Med 1999 Jul, 160(1):93-99.
44. Brightling C.E., Green R.H., Pavord I.D. Biomarkers predicting response to corticosteroid therapy in asthma. Treat Respir Med 2005, 4(5):309-316. [Review].
45. Djukanovic R., Wilson S.J., Kraft M., Jarjour N.N., Steel M., Chung K.F., et al. Treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004 Sep 15, 170(6):583-593.
46. Gauvreau G.M., Sulakvelidze I., Watson R.M., Inman M.D., Rerecich T.J., O'Byrne P.M. Effects of once daily dosing with inhaled budesonide on airway hyperresponsiveness and airway inflammation following repeated low-dose allergen challenge in atopic asthmatics. Clin Exp Allergy 2000 Sep, 30(9):1235-1243.
47. Inman M.D., Watson R.M., Rereich T., Gauvraeu G.M., Lutsky B.N., Strysak P., et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med 2001 Aug 15, 164(4):569-574.
48. Bacci E., Di Franco A., Bartoli M.L., Carnevali S., Cianchetti S., Dente F.L., et al. Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma. Eur Respir J 2002 Jul 1, 20(1):66-72.
49. Godon P., Boulet L.P., Malo J.L., Cartier A., Lemiere C. Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids. Eur Respir J 2002 Dec 1, 20(6):1364-1369.
50. Jayaram L., Pizzichini E., Lemiere C., Man S.F.P., Cartier A., Hargreave F.E., et al. Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast. Thorax 2005 Feb 1, 60(2):100-105.
51. Green R.H., Brightling C.E., McKenna S., Hargadon B., Parker D., Bradding P., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002 Nov 30, 360(9347):1715-1721.
52. Efthimiadis A., Spanevello A., Hamid Q., Kelly M.M., Linden M., Louis R., et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridization. Eur Respir J 2002 Jul 1, 20(37 Suppl.):19S-23S.
53. Stockley R.A., Bayley D.L. Validation of assays for inflammatory mediators in sputum. Eur Respir J 2000 Apr 1, 15(4):778-781.
54. Kelly M.M., Keatings V., Leigh R., Peterson C., Shute J., Venge P., et al. Analysis of fluid-phase mediators. Eur Respir J 2002 Jul 1, 20(37 Suppl.):24S-39S.
55. Erin E.M., Jenkins G.R., Kon O.M., Zacharasiewicz A.S., Nicholson G.C., Neighbour H., et al. Optimized dialysis and protease inhibition of sputum dithiothreitol supernatants. Am J Respir Crit Care Med 2008 Jan 15, 177(2):132-141.
56. Efthimiadis A., Pizzichini M.M., Pizzichini E., Dolovich J., Hargreave F.E. Induced sputum cell and fluid-phase indices of inflammation: comparison of treatment with dithiothreitol vs phosphate-buffered saline. Eur Respir J 1997 Jun 1, 10(6):1336-1340.
57. Perng D.W., Huang H.Y., Lee Y.C., Perng R.P. leukotriene modifier vs inhaled corticosteroid in mild-to-moderate asthma: clinical and anti-inflammatory effects. Chest 2004 May 1, 125(5):1693-1699.
58. Cianchetti S., Bacci E., Ruocco L., Bartoli M.L., Ricci M., Pavia T., et al. Granulocyte markers in hypertonic and isotonic saline-induced sputum of asthmatic subjects. Eur Respir J 2004 Dec 1, 24(6):1018-1024.
59. in 't Veen J.C., de Gouw H.W., Smits H.H., Sont J.K., Hiemstra P.S., Sterk P.J., et al. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. Eur Respir J 1996 Dec 1, 9(12):2441-2447.
60. Boulay M.E., Prince P., Deschesnes F., Chakir J., Boulet L.P. Metalloproteinase-9 in induced sputum correlates with the severity of the late allergen-induced asthmatic response. Respiration 2004 May, 71(3):216-224.
61. Cataldo D.D., Bettiol J., Noel A., Bartsch P., Foidart J.M., Louis R. Matrix metalloproteinase-9, but not tissue inhibitor of matrix metalloproteinase-1, increases in the sputum from allergic asthmatic patients after allergen challenge. Chest 2002 Nov 1, 122(5):1553-1559.
62. Hoshino M., Nakamura Y., Sim J., Shimojo J., Isogai S. Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation. J Allergy Clin Immunol 1998 Nov, 102(5):783-788.
63. Ko F.W.S., Diba C., Roth M., McKay K., Johnson P.R.A., Salome C., et al. A comparison of airway and serum matrix metalloproteinase-9 activity among normal subjects, asthmatic patients, and patients with asthmatic mucus hypersecretion. Chest 2005 Jun 1, 127(6):1919-1927.
64. Mattos W., Lim S., Russell R., Jatakanon A., Chung K.F., Barnes P.J. Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge, and inhaled corticosteroids. Chest 2002 Nov 1, 122(5):1543-1552.
65. Vignola A., Riccobono L., Mirabella A., Profita M., Chanze P., Bellia V., et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998 Dec 1, 158(6):1945-1950.
66. Berry M.A., Parker D., Neale N., Woodman L., Morgan A., Monk P., et al. Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2004 Nov, 114(5):1106-1109.
67. Hadjicharalambous C., Dent G., May R.D., Handy R.L., Anderson I.K., Davies D.E., et al. Measurement of eotaxin (CCL11) in induced sputum supernatants: validation and detection in asthma. J Allergy Clin Immunol 2004 Apr, 113(4):657-662.
68. Kelly M.M., Leigh R., Carruthers S., Horsewood P., Gleich G.J., Hargreave F.E., et al. Increased detection of interleukin-5 in sputum by addition of protease inhibitors. Eur Respir J 2001 Oct, 18(4):685-691.
69. Gibson P.G., Simpson J.L., Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001 May 1, 119(5):1329-1336.
70. Norzila M.Z., Fakes K., Henry R.L., Simpson J., Gibson P.G. Interleukin-8 secretion and neutrophil recruitment accompanies induced sputum eosinophil activation in children with acute asthma. Am J Respir Crit Care Med 2000 Mar 1, 161(3):769-774.
71. Diamant Z., Sampson A.P. Anti-inflammatory mechanisms of leukotriene modulators. Clin Exp Allergy 1999 Nov, 29(11):1449-1453.
72. Dworski R. Oxidant stress in asthma. Thorax 2000 Oct 1, 55(90002):51S-53S.
73. McFarlane A.J., Dworski R., Sheller J.R., Pavord I.D., Barry K.A., Barnes N.C. Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics. Am J Respir Crit Care Med 2000 May 1, 161(5):1553-1558.
74. Pavord I.D., Ward R., Woltmann G., Wardlaw A.J., Sheller J.R., Dworski R. Induced sputum eicosanoid concentrations in asthma. Am J Respir Crit Care Med 1999 Dec 1, 160(6):1905-1909.
75. Lex C., Payne D.N., Zacharasiewicz A., Li A.M., Wilson N.M., Hansel T.T., et al. Sputum induction in children with difficult asthma: safety, feasibility, and inflammatory cell pattern. Pediatr Pulmonol 2005 Apr, 39(4):318-324.
76. Wood L.G., Garg M.L., Simpson J.L., Mori T.A., Croft K.D., Wark P.A.B., et al. Induced sputum 8-isoprostane concentrations in inflammatory airway diseases. Am J Respir Crit Care Med 2005 Mar 1, 171(5):426-430.
77. Grootendorst D.C., Sont J.K., Willems L.N., Kluin-Nelemans J.C., Van Krieken J.H., Veselic-Charvat M., et al. Comparison of inflammatory cell counts in asthma: induced sputum vs bronchoalveolar lavage and bronchial biopsies. Clin Exp Allergy 1997, 27(7):769-779.
78. Vlachos-Mayer H., Leigh R., Sharon R.F., Hussack P., Hargreave F.E. Success and safety of sputum induction in the clinical setting. Eur Respir J 2000, 16(5):997-1000.
79. Petsky H.L., Kynaston J.A., Turner C., Li A.M., Cates C.J., Lasserson T.J., et al. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev 2007, (2):CD005603.
80. de Kluijver J., Evertse C.E., Schrumpf J.A., van der Veen H., Zwinderman A.H., Hiemstra P.S., et al. Asymptomatic worsening of airway inflammation during low-dose allergen exposure in asthma: protection by inhaled steroids. Am J Respir Crit Care Med 2002, 166(3):294-300.
81. Truyen E., Coteur L., Dilissen E., Overbergh L., Dupont L.J., Ceuppens J.L., et al. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. Thorax 2006, 61(3):202-208.
82. Brasier A.R., Victor S., Boetticher G., Ju H., Lee C., Bleecker E.R., et al. Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. J Allergy Clin Immunol 2008, 1211:30-37.
83. Mutlu G.M., Garey K.W., Robbins R.A., Danziger L.H., Rubinstein I. Collection and analysis of exhaled breath condensate in humans. Am J Respir Crit Care Med 2001, 164(5):731-737.
84. Scheideler L., Manke H.G., Schwulera U., Inacker O., Hammerle H. Detection of nonvolatile macromolecules in breath. A possible diagnostic tool?. Am Rev Respir Dis 1993, 148(3):778-784.
85. Horvath I., Hunt J., Barnes P.J. On behalf of the ATS/ERS task force on exhaled breath condensate. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005, 26(3):523-548.
86. Ferreira I.M., Hazari M.S., Gutierrez C., Zamel N., Chapman K.R. Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: effects of inhaled beclomethasone. Am J Respir Crit Care Med 2001, 164(6):1012-1015.
87. Hunt J. Exhaled breath condensate: an evolving tool for noninvasive evaluation of lung disease. J Allergy Clin Immunol 2002, 110(1):28-34.
88. van Beurden W.J., Harff G.A., Dekhuijzen P.N., van den Bosch M.J., Creemers J.P., Smeenk F.W. An efficient and reproducible method for measuring hydrogen peroxide in exhaled breath condensate. Respir Med 2002, 96(3):197-203.
89. Hoffmeyer F., Raulf-Heimsoth M., Harth V., Bünger J., Brüning T. Comparative analysis of selected exhaled breath biomarkers obtained with two different temperature-controlled devices. BMC Pulm Med 2009 Nov 30, 9:48.
90. Martin A.N., Farquar G.R., Jones A.D., Frank M. Human breath analysis: methods for sample collection and reduction of localized background effects. Anal Bioanal Chem 2010 Jan, 396(2):739-750.
91. Antczak A., Kurmanowska Z., Kasielski M., Nowak D. Inhaled glucocorticosteroids decrease hydrogen peroxide level in expired air condensate in asthmatic patients. Respir Med 2000, 94(5):416-421.
92. Emelyanov A., Fedoseev G., Abulimity A., Rudinski K., Fedoulov A., Karabanov A., et al. Elevated concentrations of exhaled hydrogen peroxide in asthmatic patients. Chest 2001, 120(4):1136-1139.
93. Van Hoydonck P.G.A., Wuyts W.A., Vanaudenaerde B.M., Schouten E.G., Dupont L.J., Temme E.H.M. Quantitative analysis of 8-isoprostane and hydrogen peroxide in exhaled breath condensate. Eur Respir J 2004, 23(2):189-192.
94. Nowak D., Antczak A., Krol M., Pietras T., Shariati B., Bialasiewicz P., et al. Increased content of hydrogen peroxide in the expired breath of cigarette smokers. Eur Respir J 1996, 9(4):652-657.
95. Jobsis Q., Raatgeep H.C., Hermans P.W., de Jongste J.C. Hydrogen peroxide in exhaled air is increased in stable asthmatic children. Eur Respir J 1997, 10(3):519-521.
96. Cap P., Chladek J., Pehal F., Maly M., Petru V., Barnes P.J., et al. Gas chromatography/mass spectrometry analysis of exhaled leukotrienes in asthmatic patients. Thorax 2004, 59(6):465-470.
97. Csoma Z., Kharitonov S.A., Balint B., Bush A., Wilson N.M., Barnes P.J. Increased leukotrienes in exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med 2002, 166(10):1345-1349.
98. Baraldi E., Carraro S., Alinovi R., Pesci A., Ghiro L., Bodini A., et al. Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations. Thorax 2003, 58(6):505-509.
99. Montuschi P., Barnes P.J., Ciabattoni G. Measurement of 8-isoprostane in exhaled breath condensate. Methods Mol Biol 2010, 594:73-84.
100. Montuschi P., Corradi M., Ciabattoni G., Nightingale J., Kharitonov S.A., Barnes P.J. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med 1999, 160(1):216-220.
101. Baraldi E., Ghiro L., Piovan V., Carraro S., Ciabattoni G., Barnes P.J., et al. Increased exhaled 8-isoprostane in childhood asthma. Chest 2003, 124(1):25-31.
102. Battaglia S., Den Hertog H., Timmers M.C., Lazeroms S.P.G., Vignola A.M., Rabe K.F., et al. Small airways function and molecular markers in exhaled air in mild asthma. Thorax 2005, 60(8):639-644.
103. Kostikas K., Papatheodorou G., Ganas K., Psathakis K., Panagou P., Loukides S. pH in expired breath condensate of patients with inflammatory airway diseases. Am J Respir Crit Care Med 2002, 165(10):1364-1370.
104. Vaughan J., Ngamtrakulpanit L., Pajewski T.N., Turner R., Nguyen T.A., Smith A., et al. Exhaled breath condensate pH is a robust and reproducible assay of airway acidity. Eur Respir J 2003, 22(6):889-894.
105. Carpagnano G.E., Barnes P.J., Francis J., Wilson N., Bush A., Kharitonov S.A. Breath condensate pH in children with cystic fibrosis and asthma: a new noninvasive marker of airway inflammation?. Chest 2004, 125(6):2005-2010.
106. Carraro S., Folesani G., Corradi M., Zanconato S., Gaston B., Baraldi E. Acid-base equilibrium in exhaled breath condensate of allergic asthmatic children. Allergy 2005, 60(4):476-481.
107. Hunt J.F., Fang K.E., Malik R.A., Snyder A.S., Malhotra N.E., Platts-Mills T.A., et al. Endogenous airway acidification. Implications for asthma pathophysiology. Am J Respir Crit Care Med 2000, 161(3):694-699.
108. Effros R.M., Dunning M.B., Biller J., Shaker R. The promise and perils of exhaled breath condensates. Am J Physiol Lung Cell Mol Physiol 2004, 287(6):L1073-L1080.
109. Czebe K., Barta I., Antus B., Valyon M., Horvbth I., Kullmann T. Influence of condensing equipment and temperature on exhaled breath condensate pH, total protein and leukotriene concentrations. Respir Med 2008, 102(5):720-725.
110. Soyer O.U., Dizdar E.A., Keskin O., Lilly C., Kalayci O. Comparison of two methods for exhaled breath condensate collection. Allergy 2006, 61(8):1016-1018.
111. Borrill Z.L., Roy K., Singh D. Exhaled breath condensate biomarkers in COPD. Eur Respir J 2008, 32(2):472-486.
112. Sack U., Scheibe R., Wötzel M., Hammerschmidt S., Kuhn H., Emmrich F. Multiplex analysis of cytokines in exhaled breath condensate. Cytometry A 2006 Mar, 69(3):169-172.
113. Carraro S., Rezzi S., Reniero F., Heberger K., Giordano G., Zanconato S., et al. Metabolomics applied to exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med 2007, 175(10):986-990.
114. de Laurentiis G., Paris D., Melck D., Maniscalco M., Marsico S., Corso G., et al. Metabonomic analysis of exhaled breath condensate in adults by nuclear magnetic resonance spectroscopy. Eur Respir J 2008, 32(5):1175-1183.
115. Carraro S., Giordano G., Reniero F., Perilongo G., Baraldi E. Metabolomics: a new frontier for research in pediatrics. J Pediatr 2009 May, 154(5):638-644.
116. Tufvesson E., Bjermer L. Methodological improvements for measuring eicosanoids and cytokines in exhaled breath condensate. Respir Med 2006, 100(1):34-38.
117. Rosias P.P., Robroeks C.M., Kester A., den Hartog G.J., Wodzig W.K., Rijkers G.T., et al. Biomarker reproducibility in exhaled breath condensate collected with different condensers. Eur Respir J 2008, 31(5):934-942.
118. ATS/ERS Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med 2005 Apr 15, 171(8):912-930.
119. Kharitonov S.A., Gonio F., Kelly C., Meah S., Barnes P.J. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J 2003 Mar 1, 21(3):433-438.
120. Silkoff P.E., Stevens A., Pak J., Bucher-Bartelson B., Martin R.J. A method for the standardized offline collection of exhaled nitric oxide. Chest 1999 Sep, 116(3):754-759.
121. Diamant Z., Boot J.D., Kamerling I., Bjermer L. Methods used in clinical development of novel anti-asthma therapies. Respir Med 2008, 102(3):332-338. [Review].
122. Kharitonov S.A., O'Connor B.J., Evans D.J., Barnes P.J. Allergen-induced late asthmatic reactions are associated with elevation of exhaled nitric oxide. Am J Respir Crit Care Med 1995 Jun, 151(6):1894-1899.
123. Jones S.L., Kittelson J., Cowan J.O., Flannery E.M., Hancox R.J., McLachlan C.R., et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 2001 Sep 1, 164(5):738-743.
124. Zacharasiewicz A., Wilson N., Lex C., Erin E.M., Li A.M., Hansel T., et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med 2005 May 15, 171(10):1077-1082.
125. Leuppi J.D., Salome C.M., Jenkins C.R., Anderson S.D., Xuan W., Marks G.B., et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001 Feb 1, 163(2):406-412.
126. Jatakanon A., Kharitonov S., Lim S., Barnes P.J. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999 Feb, 54(2):108-114.
127. Kharitonov S.A., Donnelly L.E., Montuschi P., Corradi M., Collins J.V., Barnes P.J. Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax 2002 Oct 1, 57(10):889-896.
128. Sandrini A., Ferreira I.M., Gutierrez C., Jardim J.R., Zamel N., Chapman K.R. Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma. Chest 2003 Oct, 124(4):1334-1340.
129. Straub D.A., Moeller A., Minocchieri S., Hamacher J., Sennhauser F.H., Hall G.L., et al. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J 2005 Feb 1, 25(2):289-294.
130. Jatakanon A., Lim S., Kharitonov S.A., Chung K.F., Barnes P.J. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998 Feb, 53(2):91-95.
131. Leuppi J.D., Salome C.M., Jenkins C.R., Koskela H., Brannan J.D., Anderson S.D., et al. Markers of airway inflammation and airway hyperresponsiveness inpatients with well-controlled asthma. Eur Respir J 2001 Sep 1, 18(3):444-450.
132. van Rensen E.L.J., Straathof K.C.M., Veselic-Charvat M.A., Zwinderman A.H., Bel E.H., Sterk P.J. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999 May 1, 54(5):403-408.
133. Berry M., Hargadon B., Morgan A., Shelley M., Richter J., Shaw D., et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J 2005, 25(6):986-991.
134. Cohen J., Douma W.R., ten Hacken N.H., Vonk J.M., Oudkerk M., Postma D.S. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J 2008, 31:1213-1220.
135. Puckett J.L., Taylor R.W., Leu S.Y., Guijon O.L., Aledia A.S., Galant S.P., et al. Clinical patterns in asthma based on proximal and distal airway nitric oxide categories. Respir Res 2010 Apr 28, 11(1):47.
136. Pijnenburg M.W., de Jongste J.C. Exhaled nitric oxide in childhood asthma: a review. Clin Exp Allergy 2008, 38(2):246-259.
137. Piacentini G.L., Bodini A., Peroni D.G., Miraglia del Giudice M., Costella S., Boner A.L. Reduction in exhaled nitric oxide immediately after methacholine challenge in asthmatic children. Thorax 2002, 57(9):771-773.
138. Alving K., Janson C., Nordvall L. Performance of a new hand-held device for exhaled nitric oxide measurement in adults and children. Respir Res 2006, 7:67.
139. Menzies D., Nair A., Lipworth B.J. Portable exhaled nitric oxide measurement: comparison with the "gold standard" technique. Chest 2007, 131(2):410-414.
140. Pizzimenti S., Bugiani M., Piccioni P., Heffler E., Carosso A., Guida G., et al. Exhaled nitric oxide measurements: correction equation to compare hand-held device to stationary analyzer. Respir Med 2008, 102(9):1272-1275.
141. Franklin P.J., Stick S.M. The value of FeNO measurement in asthma management: the motion against FeNO to help manage childhood asthma - reality bites. Paediatr Respir Rev 2008 Jun, 9(2):122-126.
142. Boot J.D., De Haas S., Tarasevych S., Roy C., Wang L., Amin D., et al. Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am J Respir Crit Care Med 2007, 175(5):450-457.
143. Taylor D.R., Pijnenburg M.W., Smith A.D., Jongste J.C.D. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006, 61(9):817-827.
144. Smith A.D., Cowan J.O., Brassett K.P., Filsell S., McLachlan C., Monti-Sheehan G., et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005, 172(4):453-459.
145. Fortuna A.M., Feixas T., Gonzalez M., Casan P. Diagnostic utility of inflammatory biomarkers in asthma: exhaled nitric oxide and induced sputum eosinophil count. Respir Med 2007, 101(11):2416-2421.
146. Smith A.D., Cowan J.O., Filsell S., McLachlan C., Monti-Sheehan G., Jackson P., et al. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med 2004, 169(4):473-478.
147. Pijnenburg M.W., Bakker E.M., Hop W.C., de Jongste J.C. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005, 172(7):831-836.
148. Szefler S.J., Mitchell H., Sorkness C.A., Gergen P.J., O'Connor G.T., Morgan W.J., et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008, 372(9643):1065-1072.
149. de Jongste J.C., Carraro S., Hop W.C., Baraldi E. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am J Respir Crit Care Med 2009, 179(2):93-97.
150. Petsky H.L., Cates C.J., Li A.M., Kynaston J.A., Turner C., Chang A.B. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev 2009 Oct, 7(4):CD006340.
151. Pauling L., Robinson A.B., Teranishi R.R., Cary P. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc Natl Acad Sci U S A 1971, 68:2374-2376.
152. Phillips M., Greenberg J. Method for the collection and analysis of volatile compounds in the breath. J Chromatogr 1991, 564:242-249.
153. Moser B., Bodrogi F., Eibl G., Lechner M., Rieder J., Lirk P. Mass spectrometric profile of exhaled breath. Field study by PTR-MS. Respir Physiol Neurobiol 2005, 145:295-300.
154. Phillips M. Method for the collection and assay of volatile organic compounds in breath. Anal Biochem 1997, 247:272-278.
155. D'Amico A., Di Natale C., Paolesse R., Macagnano A., Martinelli E., Pennazza G., et al. Olfactory systems for medical applications. Sens Actuators B 2008, 130:458-465.
156. Röck F., Barsan N., Weimar U. Electronic nose: current status and future trends. Chem Rev 2008, 108:705-713.
157. Lewis N.S. Comparisons between mammalian and artificial olfaction based on arrays of carbon black-polymer composite vapor detectors. Acc Chem Res 2004, 37:663-672.
158. Thaler E.R., Hanson C.W. Medical application of electronic nose technology. Expert Rev Med Dev 2005, 2:559-566.
159. Friedrich M.J. Scientists seek to sniff out diseases: electronic "noses" may someday be diagnostic tools. JAMA 2009, 301:585-586.
160. Dragonieri S., Schot R., Mertens B.J., Le Cessie S., Gauw S.A., Spanevello A., et al. An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol 2007, 120:856-862.
161. Montuschi P., Santonico M., Pennazza G., Mondino C., Mantini G., Martinelli E., et al. Diagnostic performance of an electronic nose, fractional exhaled nitric oxide, and lung function testing in asthma. Chest 2010, 137:790-796.
162. Scott S.M., James D., Ali Z. Data analysis for electronic nose systems. Microchim Acta 2006, 156:183-207.
163. Auffray C., Chen Z., Hood L. Systems medicine: the future of medical genomics and healthcare. Genome Med 2009, 1:2.
164. Broadhurst D.I., Kell D.B. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2006, 2:171-196.
165. Skaham O., Carmel L., Harel D. On mappings between electronic noses. Sensors Actuators B Chem 2005, 106:76-82.
166. Machado R.F., Laskowski D., Deffenderfer O., Burch T., Zheng S., Mazzone P.J., et al. Detection of lung cancer by sensor array analysis of exhaled breath. Am J Respir Crit Care Med 2005, 171:1286-1291.
167. Mazzone P.J., Hammel J., Dweik R., Na J., Czich C., Laskowski D., et al. Diagnosis of lung cancer by analysis of exhaled breath with a colorimetric sensor array. Thorax 2007, 62:565-568.
168. Peng G., Tisch U., Adams O., Hakim M., Shehada N., Broza Y.Y., et al. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol 2009, 4:669-673.
169. D'Amico A., Pennazza G., Santonico M., Martinelli E., Roscioni C., Galluccio G., et al. An investigation on electronic nose diagnosis of lung cancer. Lung Cancer 2010, 68:170-176.
170. Dragonieri S., Annema J.T., Schot R., van der Schee M.P.C., Spanevello A., Carratu P., et al. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer 2009, 64:166-170.
171. Fens N., Zwinderman A.H., van der Schee M.P., de Nijs S.B., Dijkers E., Roldaan A.C., et al. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med 2009, 180:1076-1082.
172. Fend R., Kolk A.H.J., Bessant C., Buijtels P., Klatser P.R., Woodman A.C. Prospects for clinical application of electronic nose technology to early detection of Mycobacterium tuberculosis in culture and sputum. J Clin Microbiol 2006, 44:2039-2045.
173. Thaler E.R., Huang D., Giebeig L., Palmer J., Lee D., Hansen J.W., et al. Use of an electronic nose for detection of biofilms. Am J Rhinol 2008, 22:29-33.
174. Knottnerus J.A., Muris J.W. Assessment of the accuracy of diagnostic tests: the cross-sectional study. J Clin Epidemiol 2003, 56:1118-1128.
175. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003, 138:W1-W12.
176. Gluud C., Gluud L.L. Evidence based diagnostics. BMJ 2005, 330:724-726.
177. Fens N, Rodaan AC, Bel EH, Sterk PJ. External validation of exhaled breath molecular profiling in identifying COPD and asthma. ATS Meeting A3727 [abstract].
178. Nathan R.A., Eccles R., Howarth P.H., Steinsvåg S.K., Togias A. Objective monitoring of nasal patency and nasal physiology in rhinitis. J Allergy Clin Immunol 2005 Mar, 115(3 Suppl. 1):S442-S459. [Review].
179. Naclerio R.M., Proud D., Togias A.G., Adkinson N.F., Meyers D.A., Kagey-Sobotka A., et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985, 313:65-70.
180. Greiff L., Pipkorn U., Alkner U., Persson C.G. The 'nasal pool' device applies controlled concentrations of solutes on human nasal airway mucosa and samples its surface exudations/secretions. Clin Exp Allergy 1990, 20:253-259.
181. Belda J., Parameswaran K., Keith P.K., Hargreave F.E. Repeatability and validity of cell and fluid-phase measurements in nasal fluid: a comparison of two methods of nasal lavage. Clin Exp Allergy 2001, 31:1111-1115.
182. Boot J.D., Chandoesing P., de Kam M.L., Mascelli M.A., Das A.M., Gerth van Wijk R., et al. Applicability and reproducibility of measurements of biomarkers in allergic rhinitis. J Investig Allergol Clin Immunol 2008, 18(6):433-442.
183. Grunberg K., Timmers M.C., Smits H.H., de Klerk E.P., Dick E.C., Spaan W.J., et al. Effect of experimental rhinovirus 16 colds on airway hyperresponsiveness to histamine and interleukin-8 in nasal lavage in asthmatic subjects in vivo. Clin Exp Allergy 1997, 27(1):36-45.
184. Erin E.M., Zacharasiewicz A.S., Nicholson G.C., Tan A.J., Higgins L.A., Williams T.J., et al. Topical corticosteroid inhibits interleukin-4, -5 and -13 in nasal secretions following allergen challenge. Clin Exp Allergy 2005, 35(12):1608-1614.
185. Chawes B.L., Edwards M.J., Shamji B., Walker C., Nicholson G.C., Tan A.J., et al. A novel method for assessing unchallenged levels of mediators in nasal epithelial lining fluid. J Allergy Clin Immunol 2010, 125(6):1387-1389.
186. Lü F.X., Esch R.E. Novel nasal secretion collection method for the analysis of allergen specific antibodies and inflammatory biomarkers. J Immunol Methods 2010 Apr 30, 356(1-2):6-17.
187. Godthelp T., Holm A.F., Fokkens W.J., Doornenbal P., Mulder P.G., Hoefsmit E.C., et al. Dynamics of nasal eosinophils in response to a nonnatural allergen challenge in patients with allergic rhinitis and control subjects: a biopsy and brush study. J Allergy Clin Immunol 1996, 97(3):800-811.
188. Boot J.D., Chandoesing P., De Kam M.L., Mascelli M.A., Miller B., Gerth van Wijk R., et al. Nasal nitric oxide: longitudinal reproducibility and the effects of a nasal allergen challenge in patients with allergic rhinitis. Allergy 2007, 62(4):378-384.
189. Struben V.M., Wieringa M.H., Feenstra L., de Jongste J.C. Nasal nitric oxide and nasal allergy. Allergy 2006 Jun, 61(6):665-670. [Review].
190. Naclerio R.M., Meier H.L., Kagey-Sobotka A., Adkinson N.F., Meyers D.A., Norman P.S., et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983, 128:597-602.
191. Howarth P.H., Persson C.G., Meltzer E.O., Jacobson M.R., Durham S.R., Silkoff P.E. Objective monitoring of nasal airway inflammation in rhinitis. J Allergy Clin Immunol 2005, 115:S414-S441.
192. de Graaf-in't Veld C., Garrelds I.M., Jansen A.P., Van Toorenenbergen A.W., Mulder P.G., Meeuwis J., et al. Effect of intranasal fluticasone propionate on the immediate and late allergic reaction and nasal hyperreactivity in patients with a house dust mite allergy. Clin Exp Allergy 1995, 25:966-973.
193. van Wijk R.G., Zijlstra F.J., van Toorenenbergen A.W., Vermeulen A., Dieges P.H. Isolated early response after nasal allergen challenge is sufficient to induce nasal hyperreactivity. Ann Allergy 1992, 69:43-47.
194. Belkowski S.M., Boot J.D., Mascelli M.A., Diamant Z., de Garavilla L., Hertzog B., et al. Cleaved secretory leucocyte protease inhibitor as a biomarker of chymase activity in allergic airway disease. Clin Exp Allergy 2009, 39:1179-1186.
195. Jacobson M.R., Juliusson S., Lowhagen O., Balder B., Kay A.B., Durham S.R. Effect of topical corticosteroids on seasonal increases in epithelial eosinophils and mast cells in allergic rhinitis: a comparison of nasal brush and biopsy methods. Clin Exp Allergy 1999, 29:1347-1355.
196. Terada N., Hamano N., Kim W.J., Hirai K., Nakajima T., Yamada H., et al. The kinetics of allergen-induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa. Am J Respir Crit Care Med 2001, 164:575-579.
197. Di Lorenzo G., Mansueto P., Melluso M., Candore G., Colombo A., Pellitteri M.E., et al. Allergic rhinitis to grass pollen: measurement of inflammatory mediators of mast cell and eosinophils in native nasal fluid lavage and in serum out of and during pollen season. J Allergy Clin Immunol 1997, 100:832-837.
198. Persson C.G., Erjefalt J.S., Greiff L., Andersson M., Erjefalt I., Godfrey R.W., et al. Plasma-derived proteins in airway defence, disease and repair of epithelial injury. Eur Respir J 1998, 11:958-970.
199. de Graaf-in t Veld C., Garrelds I.M., Koenders S., Gerth van Wijk R. Relationship between nasal hyperreactivity, mediators and eosinophils in patients with perennial allergic rhinitis and controls. Clin Exp Allergy 1996, 26:903-908.
200. Raphael G.D., Druce H.M., Baraniuk J.N., Kaliner M.A. Pathophysiology of rhinitis. 1. Assessment of the sources of protein in methacholine-induced nasal secretions. Am Rev Respir Dis 1988, 138:413-420.
201. Greiff L., Persson C.G., Svensson C., Enander I., Andersson M. Loratadine reduces allergen-induced mucosal output of alpha 2-macroglobulin and tryptase in allergic rhinitis. J Allergy Clin Immunol 1995, 96:97-103.
202. Meyer P., Andersson M., Persson C.G., Greiff L. Steroid-sensitive indices of airway inflammation in children with seasonal allergic rhinitis. Pediatr Allergy Immunol 2003, 14:60-65.
203. Svensson C., Andersson M., Greiff L., Blychert L.O., Persson C.G. Effects of topical budesonide and levocabastine on nasal symptoms and plasma exudation responses in seasonal allergic rhinitis. Allergy 1998, 53:367-374.
204. Choi G.S., Park H.J., Hur G.Y., Choi S.J., Shin S.Y., Ye Y.M., et al. Vascular endothelial growth factor in allergen-induced nasal inflammation. Clin Exp Allergy 2009, 39:655-661.
205. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000, 11:617-624.
206. Maniscalco M., de Laurentiis G., Weitzberg E., Lundberg J.O., Sofia M. Validation study of nasal nitric oxide measurements using a hand-held electrochemical analyser. Eur J Clin Invest 2008, 38(3):197-200.
207. Arnal J.F., Didier A., Rami J., M'Rini C., Charlet J.P., Serrano E., et al. Nasal nitric oxide is increased in allergic rhinitis. Clin Exp Allergy 1997, 27(4):358-362.
208. Maniscalco M., Sofia M., Carratu L., Higenbottam T. Effect of nitric oxide inhibition on nasal airway resistance after nasal allergen challenge in allergic rhinitis. Eur J Clin Invest 2001, 31:462-466.
209. Lundberg J.O. Nitric oxide and the paranasal sinuses. Anat Rec (Hoboken) 2008 Nov, 291(11):1479-1484.
210. Gehring U., Oldenwening M., Brunekreef B., Wieringa M.H., Kerkhof M., Smit H.A., et al. The impact of ambient NO on online measurements of exhaled and nasal NO: the PIAMA study. Pediatr Allergy Immunol 2009, 20:665-672.
211. Kharitonov S.A., Rajakulasingam K., O'Connor B., Durham S.R., Barnes P.J. Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glucocorticoids. J Allergy Clin Immunol 1997, 99(1 Pt 1):58-64.
212. Scadding G. Nitric oxide in the airways. Curr Opin Otolaryngol Head Neck Surg 2007, 15:258-263.
213. Barnes M.L., Menzies D., Nair A.R., Hopkinson P.J., Lipworth B.J. A proof-of-concept study to assess the putative dose response to topical corticosteroid in persistent allergic rhinitis using adenosine monophosphate challenge. Clin Exp Allergy 2007, 37(5):696-703.
214. Wilson A.M., Dempsey O.J., Sims E.J., Lipworth B.J. Subjective and objective markers of treatment response in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2000, 85(2):111-114.
215. Holgate S.T. Inflammatory and structural changes in the airways of patients with asthma. Respir Med 2000, 94(Suppl. D):S3-S6.
216. Keatings V.M., Evans D.J., O'Connor B.J., Barnes P.J. Cellular profiles in asthmatic airways: a comparison of induced sputum, bronchial washings, and bronchoalveolar lavage fluid. Thorax 1997, 52:372-374.
217. Gibson P. Use of induced sputum to examine airway inflammation in childhood asthma. JACI 1998, 102:S100-S101.
218. Faul J.L., Demers E.A., Burke C.M., Poulter L.W. The reproducibility of repeat measures of airway inflammation in stable atopic asthma. Am J Respir Crit Care Med 1999, 160(5 Pt 1):1457-1461.
219. van den Toorn L.M., Overbeek S.E., de Jongste J.C., Leman K., Hoogsteden H.C., Prins J.B. Airway inflammation is present during clinical remission of atopic asthma. Am J Respir Crit Care Med 2001 Dec 1, 164(11):2107-2113.
220. Corradi M., Zinelli C., Caffarelli C. Exhaled breath biomarkers in asthmatic children. Inflamm Allergy Drug Targets 2007 Sep, 6(3):150-159.
221. Moeller A., Franklin P., Hall G.L., Horak F., Wildhaber J.H., Stick S.M. Measuring exhaled breath condensates in infants. Pediatr Pulmonol 2006, 41:184-187.
222. Franklin P.J., Turner S.W., Mutch R.C., Stick S.M. Comparison of single breath and tidal breathing exhaled nitric oxide levels in infants. Eur Respir J 2004, 23:369-372.
223. Baraldi E., Jongste Jd Measurement of exhaled nitric oxide in children. Eur J Respir Dis 2001, 20:223-237.
224. Motomura C., Odajima H., Tezuka J., Murakami Y., Moriyasu Y., Kando N., et al. Effect of age on relationship between exhaled nitric oxide and airway hyperresponsiveness in asthmatic children. Chest 2009 Aug, 136(2):519-525.
225. Gibson P.G., Henry R.L., Thomas P. Noninvasive assessment of airway inflammation in children: induced sputum, exhaled nitric oxide, and breath condensate. Eur Respir J 2000 Nov, 16(5):1008-1015. [Review].
226. Marguet C., Ghad S., Couderc L., Lubrano M. What methods can we use to measure inflammation in the asthmatic child?. Arch Pediatr 2008 Jun, 15(6):1139-1145.
227. Lex C., Ferreira F., Zacharasiewicz A., Nicholson A.G., Haslam P.L., Wilson N.M., et al. Airway eosinophilia in children with severe asthma: predictive values of noninvasive tests. Am J Respir Crit Care Med 2006 Dec 15, 174(12):1286-1291.
228. Bush A., Eber E. The value of FeNO measurement in asthma management: the motion for Yes, it's NO - or, the wrong end of the Stick!. Paediatr Respir Rev 2008 Jun, 9(2):127-131.
229. Mattes J., Storm van's Gravesande K., Reining U., Alving K., Ihorst G., Henschen M., et al. NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma. Eur Respir J 1999 Jun, 13(6):1391-1395.
230. Thomas P.S., Gibson P.G., Wang H., Shah S., Henry R.L. The relationship of exhaled nitric oxide to airway inflammation and responsiveness in children. J Asthma 2005 May, 42(4):291-295.
231. Aydin A., Taira B., Singer A. Measurement of exhaled nitric oxide in the emergency department in patients with asthma. Emerg Med Clin North Am 2008 Nov, 26(4):899-904. vii.
232. Pijnenburg M.W., Hofhuis W., Hop W.C., De Jongste J.C. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax 2005 Mar, 60(3):215-218.
233. Smith A.D., Cowan J.O., Brassett K.P., Herbison G.P., Taylor D.R. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005 May 26, 352(21):2163-2173.
234. Pijnenburg M.W., Bakker E.M., Lever S., Hop W.C., De Jongste J.C. High fractional concentration of nitric oxide in exhaled air despite steroid treatment in asthmatic children. Clin Exp Allergy 2005 Jul, 35(7):920-925.
235. Carraro S., Gottardi G., Bonetto G., Baraldi E. Exhaled nitric oxide in children with asthma and sinusitis. Pediatr Allergy Immunol 2007 Nov, 18(Suppl. 18):28-30.
236. Simpson J.L., Wood L.G., Gibson P.G. Inflammatory mediators in exhaled breath, induced sputum and saliva. Clin Exp Allergy 2005, 35:1180-1185.